Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
Yuxiong Jiang, Youdong Chen, Qian Yu, et al.
BioDrugs (2023) Vol. 37, Iss. 1, pp. 35-55
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Ameliorative effects of topical ramelteon on imiquimod-induced psoriasiform inflammation in mice
Ahmed Wahhab Mohammed Khafaji, Adeeb Ahmed Kadhim Al-Zubaidy, Iqbal Farhood, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2024) Vol. 397, Iss. 8, pp. 6231-6248
Closed Access | Times Cited: 14
Inflammation and Psoriasis: A Comprehensive Review
Alessandra-Mădălina Man, Meda Sandra Orăsan, Oana-Alina Hoteiuc, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 22, pp. 16095-16095
Open Access | Times Cited: 31
Alleviative effects of combined topical melatonin and rutin on imiquimod-induced psoriasis mouse model
Shan Mohammed Khorsheed, Ahmed R. Abu‐Raghif, H. Salman
Pharmacia (2024) Vol. 71, pp. 1-13
Open Access | Times Cited: 11
Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 4, pp. 841-852
Open Access | Times Cited: 5
An overview of small-molecule agents for the treatment of psoriasis
Zhiheng Jin, Gang Li, Dengqin He, et al.
Bioorganic & Medicinal Chemistry (2025) Vol. 119, pp. 118067-118067
Closed Access
Vascular Cell Adhesion Molecule 1 and E-Selectin as Potential Cardiovascular Risk Biomarkers in Psoriasis
Natalia Joanna Machoń, Natalia Zdanowska, Paulina Klimek-Trojan, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 792-792
Open Access
Targeting IL‐23 with Small Molecule Inhibitors: A New Horizon In Psoriasis Therapy
Raghad Sharbaji, Pınar Si̇yah
ChemistrySelect (2025) Vol. 10, Iss. 8
Closed Access
Emerging treatments for dermatologic diseases in infants, children, and adolescents: a systematic review of clinical trials on biologics and small molecule inhibitors.
Alireza Jafarzadeh, Elham Behrangi, Mina Khosravi, et al.
PubMed (2025)
Closed Access
The emerging role of neutrophil extracellular traps in autoimmune and autoinflammatory diseases
Liuting Zeng, Xiang Wang, Wei Xiao, et al.
MedComm (2025) Vol. 6, Iss. 3
Open Access
The ameliorative effects of topical gemifloxacin alone or in combination with clobetasol propionate on imiquimod-induced model of psoriasis in mice
H. Salman, Adeeb Ahmed Kadhim Al-Zubaidy, Alaa Hamza Abbas, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2023) Vol. 397, Iss. 1, pp. 599-616
Closed Access | Times Cited: 15
JAK Inhibitors in Psoriatic Disease
Matteo Megna, Luca Potestio, Angelo Ruggiero, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 3129-3145
Open Access | Times Cited: 14
Attenuated effects of topical vinpocetine in an imiquimod-induced mouse model of psoriasis
H. Salman, Adeeb A. Al-Zubaidy, Alaa Hamza Abbas, et al.
Journal of Taibah University Medical Sciences (2023) Vol. 19, Iss. 1, pp. 35-53
Open Access | Times Cited: 12
Effects of tumor necrosis factor-alpha inhibitors on lipid profiles in patients with psoriasis: a systematic review and meta-analysis
Liang Su, Chunyan Xu, Hong Huang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Current and emerging prospects in the psoriatic treatment
Rutuja Vilas Nikam, M Gowtham, Pratiksha Sanjay More, et al.
International Immunopharmacology (2023) Vol. 120, pp. 110331-110331
Closed Access | Times Cited: 10
Brilaroxazine lipogel displays antipsoriatic activity in imiquimod‐induced mouse model
Laxminarayan Bhat, Seema R. Bhat, Arulprakash Ramakrishnan, et al.
Skin Research and Technology (2024) Vol. 30, Iss. 2
Open Access | Times Cited: 3
Effects on Lipid Profile after One Year of Apremilast Therapy in Patients with Psoriasis: A Monocentric Experience
Prisca Guerra, Antonella Di Cesare, Elia Rosi, et al.
Life (2024) Vol. 14, Iss. 3, pp. 395-395
Open Access | Times Cited: 3
Switching pattern of biological drugs in patients with psoriasis and psoriatic arthritis: insight from the VALORE database network
Andrea Spini, Giorgia Pellegrini, Ylenia Ingrasciotta, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 5, pp. 399-409
Closed Access | Times Cited: 3
A novel online calculator based on clinical features and hematological parameters to predict total skin clearance in patients with moderate to severe psoriasis
Yuxiong Jiang, Dawei Huang, Qianyu Chen, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 2
Psoriasis Comorbidities and Their Treatment Impact
Mark Taliercio, Mark Lebwohl
Dermatologic Clinics (2024) Vol. 42, Iss. 3, pp. 405-416
Closed Access | Times Cited: 2
Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities
Laura Mateu Arrom, L. Puig
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 4, pp. 363-379
Closed Access | Times Cited: 2
Safety and effectiveness of guselkumab in Japanese patients with psoriasis: 20‐week interim analysis of a postmarketing surveillance study
Yayoi Tada, Yukako Sugiura, Manami Kamishima, et al.
The Journal of Dermatology (2024) Vol. 51, Iss. 6, pp. 779-790
Open Access | Times Cited: 2
Psoriasis management tree based on comorbidity
S. Abu Amara, Anusha Pasumarthi, Neil Parikh, et al.
International Journal of Dermatology (2024)
Closed Access | Times Cited: 2
An Insight on the Possible Association between Inflammatory Bowel Disease and Biologic Therapy with IL-17 Inhibitors in Psoriasis Patients
Olguța Anca Orzan, Cristian Tieranu, Andrei Ovidiu Olteanu, et al.
Pharmaceutics (2023) Vol. 15, Iss. 8, pp. 2171-2171
Open Access | Times Cited: 7
Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review
Giampiero Girolomoni, L. Savage, Paolo Gisondi, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 10, pp. 2171-2185
Open Access | Times Cited: 7
The Expression of Activation Markers CD25 and CD69 Increases during Biologic Treatment of Psoriasis
Michał Adamczyk, Joanna Bartosińska, Dorota Raczkiewicz, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 20, pp. 6573-6573
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top